Therapeutic advances occurred these last years rather for Crohn's disease than for ulcerative colitis. For Crohn's disease the impressive effectiveness of infliximab is confirmed; thalidomide is considered as an outsider, long-term safety for both treatments is still of great concern. For ulcerative colitis use of probiotics could be promising; practical modalities in use of mesalazine and ciclosporine are better defined.
Mendeley saves you time finding and organizing research
Choose a citation style from the tabs below